Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis

M. A. Thorat, C. Marchio, A. Morimiya, K. Savage, Harikrishna Nakshatri, J. S. Reis-Filho, Sunil Badve

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Aims: Forkhead box A1 (FOXA1) is a forkhead family transcription factor expressed in breast cancer cells. It is essential for optimal expression of ∼50% of oestrogen receptor (ER)-related genes. This study explored the FOXA1 relationship with luminal and basal breast cancer subtypes, proliferation markers, and survival in breast cancer patients who had received similar treatment. Methods: A tissue microarray comprising tumours from 245 invasive breast cancer patients with 67 months of median follow-up was analysed for FOXA1 expression by immunohistochemistry. Interpretable FOXA1 expression, obtained in 184 patients, was analysed along with other variables such as tumour grade, size, nodal status, ER, progesterone receptor, HER2/neu, proliferation and basal markers. Results: FOXA1 expression (score >3) was seen in 139 of 184 breast cancers. It correlated positively with ERα (p<0.0001), progesterone receptor (p<0.0001), and luminal subtype (p<0.0001); negatively with basal subtype (p<0.0001), proliferation markers and high histological grade (p = 0.0327). Univariate analysis showed nodal status, tumour grade, ER, progesterone receptor, FOXA1, basal markers and p53 as significant predictors of overall survival. Multivariate analysis showed that only nodal status (p = 0.0006) and ER (p = 0.0017) were significant predictors of OS. In luminal subtype patient subgroup, FOXA1 expression was associated with better survival (p = 0.0284) on univariate analysis. Conclusion: Based on this study in patients treated with surgery followed by adjuvant anthracycline-based chemotherapy, FOXA1 expression is associated with good prognosis. It correlates with luminal subtype breast cancer, and could possibly serve as a clinical marker for luminal subtype A. Prognostic ability of FOXA1 in these low-risk breast cancers may prove to be useful in treatment decision making.

Original languageEnglish
Pages (from-to)327-332
Number of pages6
JournalJournal of Clinical Pathology
Volume61
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Breast Neoplasms
Progesterone Receptors
Survival
Forkhead Transcription Factors
Neoplasms
Aptitude
Anthracyclines
Estrogen Receptors
Decision Making
Multivariate Analysis
Biomarkers
Immunohistochemistry
Drug Therapy
Therapeutics
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. / Thorat, M. A.; Marchio, C.; Morimiya, A.; Savage, K.; Nakshatri, Harikrishna; Reis-Filho, J. S.; Badve, Sunil.

In: Journal of Clinical Pathology, Vol. 61, No. 3, 03.2008, p. 327-332.

Research output: Contribution to journalArticle

Thorat, M. A. ; Marchio, C. ; Morimiya, A. ; Savage, K. ; Nakshatri, Harikrishna ; Reis-Filho, J. S. ; Badve, Sunil. / Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. In: Journal of Clinical Pathology. 2008 ; Vol. 61, No. 3. pp. 327-332.
@article{e33885b9067d4ce0b84ad003c96b52f8,
title = "Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis",
abstract = "Aims: Forkhead box A1 (FOXA1) is a forkhead family transcription factor expressed in breast cancer cells. It is essential for optimal expression of ∼50{\%} of oestrogen receptor (ER)-related genes. This study explored the FOXA1 relationship with luminal and basal breast cancer subtypes, proliferation markers, and survival in breast cancer patients who had received similar treatment. Methods: A tissue microarray comprising tumours from 245 invasive breast cancer patients with 67 months of median follow-up was analysed for FOXA1 expression by immunohistochemistry. Interpretable FOXA1 expression, obtained in 184 patients, was analysed along with other variables such as tumour grade, size, nodal status, ER, progesterone receptor, HER2/neu, proliferation and basal markers. Results: FOXA1 expression (score >3) was seen in 139 of 184 breast cancers. It correlated positively with ERα (p<0.0001), progesterone receptor (p<0.0001), and luminal subtype (p<0.0001); negatively with basal subtype (p<0.0001), proliferation markers and high histological grade (p = 0.0327). Univariate analysis showed nodal status, tumour grade, ER, progesterone receptor, FOXA1, basal markers and p53 as significant predictors of overall survival. Multivariate analysis showed that only nodal status (p = 0.0006) and ER (p = 0.0017) were significant predictors of OS. In luminal subtype patient subgroup, FOXA1 expression was associated with better survival (p = 0.0284) on univariate analysis. Conclusion: Based on this study in patients treated with surgery followed by adjuvant anthracycline-based chemotherapy, FOXA1 expression is associated with good prognosis. It correlates with luminal subtype breast cancer, and could possibly serve as a clinical marker for luminal subtype A. Prognostic ability of FOXA1 in these low-risk breast cancers may prove to be useful in treatment decision making.",
author = "Thorat, {M. A.} and C. Marchio and A. Morimiya and K. Savage and Harikrishna Nakshatri and Reis-Filho, {J. S.} and Sunil Badve",
year = "2008",
month = "3",
doi = "10.1136/jcp.2007.052431",
language = "English",
volume = "61",
pages = "327--332",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis

AU - Thorat, M. A.

AU - Marchio, C.

AU - Morimiya, A.

AU - Savage, K.

AU - Nakshatri, Harikrishna

AU - Reis-Filho, J. S.

AU - Badve, Sunil

PY - 2008/3

Y1 - 2008/3

N2 - Aims: Forkhead box A1 (FOXA1) is a forkhead family transcription factor expressed in breast cancer cells. It is essential for optimal expression of ∼50% of oestrogen receptor (ER)-related genes. This study explored the FOXA1 relationship with luminal and basal breast cancer subtypes, proliferation markers, and survival in breast cancer patients who had received similar treatment. Methods: A tissue microarray comprising tumours from 245 invasive breast cancer patients with 67 months of median follow-up was analysed for FOXA1 expression by immunohistochemistry. Interpretable FOXA1 expression, obtained in 184 patients, was analysed along with other variables such as tumour grade, size, nodal status, ER, progesterone receptor, HER2/neu, proliferation and basal markers. Results: FOXA1 expression (score >3) was seen in 139 of 184 breast cancers. It correlated positively with ERα (p<0.0001), progesterone receptor (p<0.0001), and luminal subtype (p<0.0001); negatively with basal subtype (p<0.0001), proliferation markers and high histological grade (p = 0.0327). Univariate analysis showed nodal status, tumour grade, ER, progesterone receptor, FOXA1, basal markers and p53 as significant predictors of overall survival. Multivariate analysis showed that only nodal status (p = 0.0006) and ER (p = 0.0017) were significant predictors of OS. In luminal subtype patient subgroup, FOXA1 expression was associated with better survival (p = 0.0284) on univariate analysis. Conclusion: Based on this study in patients treated with surgery followed by adjuvant anthracycline-based chemotherapy, FOXA1 expression is associated with good prognosis. It correlates with luminal subtype breast cancer, and could possibly serve as a clinical marker for luminal subtype A. Prognostic ability of FOXA1 in these low-risk breast cancers may prove to be useful in treatment decision making.

AB - Aims: Forkhead box A1 (FOXA1) is a forkhead family transcription factor expressed in breast cancer cells. It is essential for optimal expression of ∼50% of oestrogen receptor (ER)-related genes. This study explored the FOXA1 relationship with luminal and basal breast cancer subtypes, proliferation markers, and survival in breast cancer patients who had received similar treatment. Methods: A tissue microarray comprising tumours from 245 invasive breast cancer patients with 67 months of median follow-up was analysed for FOXA1 expression by immunohistochemistry. Interpretable FOXA1 expression, obtained in 184 patients, was analysed along with other variables such as tumour grade, size, nodal status, ER, progesterone receptor, HER2/neu, proliferation and basal markers. Results: FOXA1 expression (score >3) was seen in 139 of 184 breast cancers. It correlated positively with ERα (p<0.0001), progesterone receptor (p<0.0001), and luminal subtype (p<0.0001); negatively with basal subtype (p<0.0001), proliferation markers and high histological grade (p = 0.0327). Univariate analysis showed nodal status, tumour grade, ER, progesterone receptor, FOXA1, basal markers and p53 as significant predictors of overall survival. Multivariate analysis showed that only nodal status (p = 0.0006) and ER (p = 0.0017) were significant predictors of OS. In luminal subtype patient subgroup, FOXA1 expression was associated with better survival (p = 0.0284) on univariate analysis. Conclusion: Based on this study in patients treated with surgery followed by adjuvant anthracycline-based chemotherapy, FOXA1 expression is associated with good prognosis. It correlates with luminal subtype breast cancer, and could possibly serve as a clinical marker for luminal subtype A. Prognostic ability of FOXA1 in these low-risk breast cancers may prove to be useful in treatment decision making.

UR - http://www.scopus.com/inward/record.url?scp=40449117593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449117593&partnerID=8YFLogxK

U2 - 10.1136/jcp.2007.052431

DO - 10.1136/jcp.2007.052431

M3 - Article

C2 - 18037662

AN - SCOPUS:40449117593

VL - 61

SP - 327

EP - 332

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 3

ER -